Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer
Journal of Medicinal Chemistry · 14.09.2023 · 66 (17) · 12033-12058
DOI: 10.1021/acs.jmedchem.3c00614 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.09.2023. Verfasst von Sravani Pulya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani Hyderabad Campus, Shamirpet, Hyderabad 50007…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: Indian Council of Medical Research, Department of Science and Technology, Ministry of Science and Technology, India, Birla Institute of Technology and Science, Pilani.
Abstract (Originalsprache)
HDAC3 modulation shows promise for breast cancer, including triple-negative cases. Novel pyrazino-hydrazide-based HDAC3 inhibitors were designed and synthesized. Lead compound 4i exhibited potent HDAC3 inhibition (IC50 = 14 nM) with at least 121-fold selectivity. It demonstrated strong cytotoxicity against triple-negative breast cancer cells (IC50: 0.55 μM for 4T1, 0.74 μM for MDA-MB-231) with least normal cell toxicity. Metabolically stable 4i displayed a superior pharmacokinetic profile. A dose-dependent therapeutic efficacy of 4i was observed in a tumor-bearing mouse model. The biomarker analysis with tumor tissues displayed enhanced acetylation on Ac-H3K9, Ac-H3K27, and Ac-H4K12 compared to Ac-tubulin and Ac-SMC3 indicating HDAC3 selectivity of 4i in vivo. The immunoblotting study with tumor tissue showed upregulation of apoptotic proteins caspase-3, caspase-7, and cytochrome c and the downregulation of proliferation markers Bcl-2, CD44, EGFR, and Ki-67. Compound 4i represents a promising candidate for targeted breast cancer therapy, particularly for cases with triple-negative breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani Hyderabad Campus, Shamirpet, Hyderabad 500078, India.
- Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani Hyderabad Campus, Shamirpet, Hyderabad 500078, India.
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, Jadavpur University, P.O. Box 17020, Kolkata, West Bengal 700032, India.
ORCID-Profile: Nilanjan Adhikari, Swati Biswas, Tarun Jha, Balaram Ghosh
Förderung
- Indian Council of Medical Research
- Department of Science and Technology, Ministry of Science and Technology, India
- Birla Institute of Technology and Science, Pilani
Zitieren
APA
Pulya, S., Himaja, A., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2023). Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 66(17), 12033-12058. https://doi.org/10.1021/acs.jmedchem.3c00614
Vancouver
Pulya S, Himaja A, Paul M, Adhikari N, Banerjee S, Routholla G, et al. Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 2023;66(17):12033-12058. doi:10.1021/acs.jmedchem.3c00614
BibTeX
@article{Pulya2023,
author = {Pulya, Sravani and Himaja, Ambati and Paul, Milan and Adhikari, Nilanjan and Banerjee, Suvankar and Routholla, Ganesh and Biswas, Swati and Jha, Tarun and Ghosh, Balaram},
title = {Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {17},
pages = {12033--12058},
doi = {10.1021/acs.jmedchem.3c00614}
}
EUVIMED